Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX21 Tepotinib
D11073 Tepotinib hydrochloride (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
MET Inhibitors
Tepotinib
D11073 Tepotinib hydrochloride (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11073 Tepotinib hydrochloride (USAN); Tepotinib hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03087 Tepotinib
D11073 Tepotinib hydrochloride
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03087 Tepotinib
D11073 Tepotinib hydrochloride
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03087 Tepotinib
D11073 Tepotinib hydrochloride
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
MET family
MET* [HSA_VAR:4233v4]
D11073 Tepotinib hydrochloride (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11073
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11073
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11073
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11073
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11073
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03087 Tepotinib
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03087 Tepotinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03087 Tepotinib